Agreement for CellREDM highlights growing interest in regenerative injectables used alongside fillers.
Hugel Inc has signed a distribution agreement with Hans Biomed to bring an extracellular matrix (ECM)-based injectable, CellREDM, to the Korean market, according to a company release.
The agreement gives Hugel domestic sales rights to CellREDM, an injectable derived from human acellular dermal matrix. The product is designed to supplement extracellular matrix components such as collagen and elastin and support skin regeneration, according to the release.
Hans Biomed, a Korea-based medical materials manufacturer, operates a tissue bank that has received approval from the American Association of Tissue Banks.
The deal represents an expansion of Hugel’s portfolio beyond its existing injectables, which include botulinum toxin and dermal fillers. According to the company, ECM-based injectables are often used alongside dermal fillers in aesthetic procedures.
Under the agreement, Hugel and Hans Biomed will use a co-promotion model focused on specialized clinics, with the goal of improving supply and market access, according to the release.
“Through our partnership with Hugel, we will leverage our innovative tissue processing technology as Korea’s first tissue bank to highlight the superior quality of CellREDM, which reduces post-procedure downtime and pain, and drive further growth,” says Geun Young Kim, CEO of Hans Biomed, in the release.
Daniel Chang, Korea CEO of Hugel, adds in a release, “We will swiftly respond to rising demand in the medical aesthetics market to further strengthen our leadership in the industry. We see this agreement as a starting point for Hugel’s business expansion and will continue to explore innovative products and opportunities in Korea and overseas.”
Hugel also says it is exploring additional aesthetic materials, including poly-L-lactic acid, polycaprolactone, polynucleotide, and polydeoxyribonucleotide, as part of its broader portfolio strategy.
Photo caption: Daniel Chang (right), Korea CEO of Hugel, and Geun Young Kim, CEO of Hans Biomed, signed an agreement on April 1 to distribute extracellular matrix-injectable treatment CellREDM in the Korean market.
Photo credit: Hugel Inc
